Human hepatocytes and cytochrome P450‐selective inhibitors predict variability in human drug exposure more accurately than human recombinant <scp>P450s</scp>

Abstract

The results suggest that variability in human drug exposure due to DDI and enzyme polymorphism can be accurately predicted using fm_CYP from human hepatocytes and CYP-selective inhibitors. This approach can be efficiently applied in drug discovery to aid optimization of candidate drugs with a favourable metabolic elimination profile and limited variability in patients.